MARKET

CLDX

CLDX

Celldex
NASDAQ

Real-time Quotes | Nasdaq Last Sale

55.21
-0.78
-1.39%
After Hours: 54.00 -1.21 -2.19% 16:53 09/24 EDT
OPEN
55.13
PREV CLOSE
55.99
HIGH
56.14
LOW
54.65
VOLUME
267.93K
TURNOVER
--
52 WEEK HIGH
56.17
52 WEEK LOW
11.55
MARKET CAP
2.57B
P/E (TTM)
-33.0698
1D
5D
1M
3M
1Y
5Y
Celldex to Present at the 2021 Cantor Virtual Global Healthcare Conference
HAMPTON, N.J., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that senior management will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on Wednesday, September 29, 2021 a...
GlobeNewswire · 19h ago
Celldex Announces Upcoming Presentation of CDX-0159 Phase 1b Results in Inducible Urticaria at the 2021 European Academy of Dermatology and Venereology (EADV) 30th Congress
Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing symptom control and quality of life measurements from the Phase 1b study of CDX-0159 in patients with antihistamine refractory cold contact urticaria (ColdU) and symptomat...
GlobeNewswire · 1d ago
Where Celldex Therapeutics Stands With Analysts
Celldex Therapeutics (NASDAQ:CLDX) has observed the following analyst ratings within the last quarter:
Benzinga · 09/17 16:06
Jefferies Initiates Coverage On Celldex Therapeutics with Buy Rating, Announces Price Target of $66
Jefferies analyst Chris Howerton initiates coverage on Celldex Therapeutics (NASDAQ:CLDX) with a Buy rating and announces Price Target of $66.
Benzinga · 09/17 12:24
Investors in Celldex Therapeutics (NASDAQ:CLDX) have made a enviable return of 729% over the past three years
Investing can be hard but the potential fo an individual stock to pay off big time inspires us. Mistakes are...
Simply Wall St. · 09/16 11:01
Celldex (CLDX) Initiates Subcutaneous Skin Disorder Drug Study
Celldex (CLDX) is developing subcutaneous as well as intravenous formulations of its antibody candidate, CDX-0159 as a potential treatment of several skin disorders.
Zacks · 09/14 14:31
HC Wainwright & Co. Maintains Buy on Celldex Therapeutics, Raises Price Target to $60
HC Wainwright & Co. analyst Joseph Pantginis maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and raises the price target from $54 to $60.
Benzinga · 09/13 16:45
--HC Wainwright Adjusts Celldex Therapeutics PT to $60 From $54, Maintains Buy Rating
MT Newswires · 09/13 13:48
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CLDX. Analyze the recent business situations of Celldex through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CLDX stock price target is 64.83 with a high estimate of 68.00 and a low estimate of 60.00.
EPS
Institutional Holdings
Institutions: 174
Institutional Holdings: 49.23M
% Owned: 105.92%
Shares Outstanding: 46.48M
TypeInstitutionsShares
Increased
31
4.02M
New
39
1.80M
Decreased
36
3.17M
Sold Out
23
1.56M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Non-Executive Chairman/Independent Director
Karen Shoos
Chief Executive Officer/President/Director
Anthony Marucci
Chief Financial Officer/Senior Vice President/Secretary
Sam Martin
Executive Vice President/Chief Scientific Officer
Tibor Keler
Senior Vice President/General Counsel
Freddy Jimenez
Senior Vice President/IR Contact Officer
Sarah Cavanaugh
Senior Vice President
Elizabeth Crowley
Senior Vice President
Margo Heath-Chiozzi
Senior Vice President
Ronald Pepin
Senior Vice President
Richard Wright
Senior Vice President
Diane Young
Independent Director
Keith Brownlie
Independent Director
Herbert Conrad
Independent Director
James Marino
Independent Director
Harry Penner
No Data
About CLDX
Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients. Its Glembatumumab vedotin (also referred to as CDX-011) is meant for the treatment of metastatic melanoma. Its Varlilumab (also referred to as CDX-1127) is an immune modulating antibody. Its earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor. It includes a multi-faceted tumor-associated macrophage (TAM) program. The Company's pipeline also includes CDX-0158 and CDX-3379, which are humanized monoclonal antibodies.

Webull offers kinds of Celldex Therapeutics, Inc. stock information, including NASDAQ:CLDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLDX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CLDX stock methods without spending real money on the virtual paper trading platform.